Radiotherapy-Associated Anemia: The Scope of the Problem
|
|
- Ami Weaver
- 6 years ago
- Views:
Transcription
1 Radiotherapy-Associated Anemia: The Scope of the Problem LOUIS B. HARRISON, DANIEL SHASHA, CAROL WHITE, BEVERLY RAMDEEN Department of Radiation Oncology, Beth Israel Medical Center, St. Luke s-roosevelt Hospital Center, New York, New York, USA Key Words. Radiotherapy Anemia Quality of life Tumor hypoxia Locoregional control ABSTRACT The impact of anemia on cancer patients undergoing chemotherapy is well established, but only recently has the prevalence of anemia in patients receiving radiotherapy received much attention. Many cancer patients present with anemia prior to radiotherapy, and even more experience anemia or a worsening of anemia at some point during treatment. However, the problem of anemia is often ignored because patients may experience only functional anemia, defined as a hemoglobin level less than 12 g/dl. Unless physiologic anemia (hemoglobin = 8 g/dl) is discovered, efforts to correct anemia are often not made. Because hemoglobin levels <12 g/dl seem to be associated with tumor hypoxia and poorer outcomes of radiotherapy in a number of patient populations, ignoring even modest anemia can result in decreased locoregional control, overall survival, and quality of life (QOL). Because increasing hemoglobin levels 1-2 g/dl is usually easily accomplished, there exists the potential for improving outcomes by paying greater attention to this problem. This article focuses on the prevalence of anemia, particularly functional anemia, and discusses the impact of anemia on locoregional control, overall survival, and QOL. The Oncologist 2;5(suppl 2): 1-7 INTRODUCTION Continuing advances in oncology care, including new radiotherapy technologies and recent developments with multimodal therapies, have significantly improved clinical outcomes and quality of life (QOL) for many patients with cancer. However, the prevalence and impact of cancer-associated anemia is not widely appreciated. Emerging data demonstrate that cancer-related anemia is unexpectedly common in cancer patients receiving radiotherapy and/or chemotherapy and that even modest anemia (hemoglobin <12 g/dl) substantially impairs QOL. In addition, a growing body of literature suggests that hemoglobin concentrations of less than g/dl during cancer therapy are associated with reduced local tumor control and decreased survival [1, 2]. Although anemia of this magnitude can be easily managed, it is often overlooked or considered clinically insignificant. However, restoration of normal hemoglobin concentrations in patients undergoing radiotherapy has the potential to improve local tumor control and survival and produce sizable improvements in patient QOL. RADIOTHERAPY-RELATED ANEMIA: THE BETH ISRAEL/ST. LUKE S-ROOSEVELT EXPERIENCE Although anemia is a recognized cancer-related disorder, recent studies have focused on its impact rather than its prevalence among patients undergoing radiotherapy [1, 3, 4]. The radiation oncology community, in general, has not placed a significant effort into the global problem of anemia in our patients, or its correction. Therefore, we are currently conducting a retrospective assessment of patient charts for patients seen at Beth Israel Medical Center and St. Luke s- Roosevelt Hospital Center between December 1996 and March To date, 22 randomly selected patients who were referred for radiation oncology evaluation, and who ultimately received radiotherapy, were included. The results show that 48% of these patients presented to our department with anemia (defined as hemoglobin <12 g/dl) and a total of 57% ultimately became anemic by the end of therapy. When stratified by sex, 32% of men and 57% of women presented with anemia, which increased to 51% of men and 64% of women by the end of treatment. These Correspondence: Louis B. Harrison, M.D., Department of Radiation Oncology, Beth Israel Medical Center, St. Luke s- Roosevelt Hospital Center, 1 Union Square East, New York, New York 13, USA. Telephone: ; Fax: ; lharrison@bethisraelny.org Received April 13, 2; accepted for publication April 21, 2. AlphaMed Press /2/$5./ The Oncologist 2;5:(suppl 2):1-7
2 2 Radiotherapy-Associated Anemia numbers indicate that anemia is a common problem for a majority of patients undergoing radiotherapy. Given the impact of anemia on local control and QOL, this is a problem that needs to be addressed in a more comprehensive manner. To assess the prevalence of anemia according to tumor type, we stratified the data according to anatomical site. The data show that for patients with breast, prostate, colorectal, lung and bronchus, and uterine-cervix cancers, the percentage experiencing anemia increased during the course of radiotherapy (Fig. 1). The most notable increase occurred in the prostate cancer group. Only 5% of patients with prostate cancer presented with anemia, but roughly one-third (32%) were anemic by the end of their treatment. More uterine-cervix cancer patients presented with anemia (67%) than any other group, and by the end of radiotherapy 82% had experienced anemia. This number will more than likely increase as more uterine-cervix cancer patients receive combination therapy. When we examined the data for uterine-cervix cancer patients with anemia, we discovered that for most patients, the severity of anemia before and during therapy was modest (Fig. 2). Of the 67% of patients who were anemic upon presentation, 44% had hemoglobin levels between 1 g/dl and 11.9 g/dl. Of the 82% who were anemic at some point during treatment, over half (59%) had hemoglobin levels between 1 g/dl and 11.9 g/dl. For both groups, 11% had hemoglobin levels between 9 g/dl and 9.9 g/dl. Only a few in either group had levels below 8.9 g/dl. Data on colorectal and prostate (Fig. 3), lung, and breast cancer patients (Table 1) yielded similar information. The current practice of treating breast cancer patients with lumpectomy and adjuvant chemotherapy prior to radiotherapy results in a high incidence of anemia among patients immediately before undergoing radiotherapy. In our study, 28 breast cancer patients received chemotherapy prior to radiotherapy. Of these, nearly 68% presented with anemia prior to radiotherapy, most (57%) having only modest anemia (hemoglobin level between 11. and 11.9 g/dl). Most of the 22 patients we reviewed so far had modest, or functional, anemia, which is often not treated. Very few had physiologic anemia (hemoglobin of 8 g/dl or less), which is more apt to receive attention. UNDERSTANDING THE IMPACT OF ANEMIA In 1951 Hollaender et al. published their study on the radiosensitivity of aerobically and anaerobically cultured Escherichia coli [5]. Their study helped form the foundation of current thinking on tumor hypoxia and its effect on radiotherapy. Under hypoxic conditions, tumors appear to be less susceptible to radiation, and clinical outcomes are poorer [6]. A recent study investigated the relationship between tumor hypoxia and tumor control and survival in patients with cervical cancer undergoing radiotherapy. The results of tumor oxygenation measurements taken prior to radiotherapy by an Eppendorf oxygen electrode and measured by the Eppendorf po 2 histograph indicate that tumor hypoxia is associated with an increased risk of relapse and death, particularly in patients with bulky hypoxic tumors. Tumor oxygenation was significantly associated with disease-free survival (p =.2), as was tumor size (p =.3), stage (p =.6), and pretreatment hemoglobin level (p =.1) [7]. The association between anemia and tumor hypoxia is not fully understood, but it is well established that low hemoglobin levels independently predict poorer survival and relapse [8-1]. However, it is not clear whether low Figure 1. Results of Beth Israel Medical Center/St. Luke s-roosevelt Hospital Center retrospective chart review assessing the incidence of anemia, defined as hemoglobin concentration <12 g/dl, before and during radiation therapy by site. The data provided are for the 22 patients reviewed to date. Percent of patients with anemia Anemia Before and During RT (by site) Baseline During therapy Breast Colon/ Lung/ Prostate Uterine- (n = 63) Rectum Bronchus (n = 19) Cervix (n = 36) (n = 1) (n = 27) Note: Anemia = Hb < 12 g/dl
3 Harrison, Shasha, White et al. 3 Table 1. Distribution of anemia before and during radiation therapy (RT) in patients with breast cancer (n = 63) in the Beth Israel Medical Center/St. Luke s-roosevelt Hospital Center retrospective chart review Patients who received Baseline During RT pre-rt chemotherapy (n = 28) n (%) n (%) n (%) All patients with anemia 26 (41.2) 28 (44.4) 19 (67.9) Hemoglobin concentrations g/dl g/dl g/dl 2 (3.2) g/dl 3 (4.8) 4 (6.3) 1 (3.6) g/dl 5 (7.9) 5 (7.9) 2 (7.1) g/dl 16 (25.4) 19 (3.2) 16 (57.1) Percent of patients with anemia Anemia in Patients with Cervical Cancer Receiving RT by Hb Levels (n = 27) All 6 g/dl 7 g/dl 8 g/dl 9 g/dl 1 g/dl 11 g/dl Patients 6.9 g/dl 7.9 g/dl 8.9 g/dl 9.9 g/dl 1.9 g/dl 11.9 g/dl Baseline During therapy Note: Anemia = Hb < 12 g/dl Figure 2. Results of Beth Israel Medical Center/St. Luke s-roosevelt Hospital Center retrospective chart review assessing the incidence of anemia, defined as hemoglobin concentration <12 g/dl, before and during radiation therapy in cervix cancer patients. The data, grouped by hemoglobin levels, are for 27 patients with cervix cancer. hemoglobin levels are associated with poor survival because they indicate advanced disease or because they indicate poor tumor oxygenation. Current thinking, however, recognizes anemia as a likely contributor to tumor hypoxia [8, 11] with a focus on anemia and locoregional failure. The impact of anemia on survival and relapse after radiotherapy has been investigated for a number of tumor types [8, 9]. A recent study looked at the association between anemia and overall survival and local tumor control in patients with locally advanced head and neck cancer undergoing radiation therapy. Patients were stratified by hemoglobin levels and were given either radiation therapy with a hypoxic cell sensitizer, etanidazole, or radiation therapy alone. The survival rate at five years for patients with anemia defined as hemoglobin concentration <14.5 g/dl for men and <13 g/dl for women was 22%. For nonanemic patients the rate at five years was 36%, a significant increase compared with anemic patients ( p =.16). Treatment with etanidazole did not significantly improve survival among any group of patients. Locoregional failure at five years differed significantly between patients with or without anemia. Patients with normal hemoglobin levels experienced locoregional failure at a rate of 52% compared with 68% for anemic patients (p =.28) [3]. Again, the addition of etanidazole did not significantly affect locore-
4 4 Radiotherapy-Associated Anemia 1 Anemia in Patients with Prostate Cancer Receiving RT by Hb Levels (n = 19) Percent of patients with anemia All 6 g/dl 7 g/dl 8 g/dl 9 g/dl 1 g/dl 11 g/dl Patients 6.9 g/dl 7.9 g/dl 8.9 g/dl 9.9 g/dl 1.9 g/dl 11.9 g/dl Baseline During Therapy Note: Anemia = Hb < 12 g/dl Figure 3. Results of Beth Israel Medical Center/St. Luke s-roosevelt Hospital Center retrospective chart review assessing the incidence of anemia, defined as hemoglobin concentration < 12 g/dl, before and during radiation therapy in patients with prostate cancer. The data, grouped by hemoglobin levels, are for 19 patients with prostate cancer. gional control among any group of patients. Anemia was significantly related to decreased survival and increased relapse rates. A strong correlation between hemoglobin levels, local control, and survival was also observed in a study of 19 patients with T1-T2 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy [9]. Patients who Local recurrence-free survival (%) p =.2 RT alone RT mito Years Figure 4. Results from the trial reported by Haffty et al. [12]. Local recurrence-free survival in patients with head and neck cancer receiving radiation plus a radiosensitizer or radiation alone as adjuvant radiotherapy after surgery. Reprinted with permission. presented with hemoglobin values >13. g/dl had significantly higher two-year rates of locoregional tumor control (95% versus 66%, p =.18) and survival (88% versus 46%, p <.1) as compared with patients with hemoglobin values <13. g/dl. Improving the efficacy of radiation therapy and, therefore, locoregional response and survival, may be achieved by addressing anemia and tumor hypoxia. Recent studies have investigated strategies that reduce anemia and tumor hypoxia such as hypoxic cell sensitizers, fluosol, carbogen breathing, hyperbaric oxygen, red blood cell transfusions, and recombinant human erythropoietin (epoetin alfa). In a study of patients with head and neck cancer given radiation and mitomycin C, a hypoxic cell sensitizer, or radiation alone, the data showed that the addition of mitomycin C significantly improved local recurrence-free survival and cause-specific survival (Figs. 4 and 5) [12]. In a preliminary study, advanced head and neck cancer patients treated with daily chemoradiotherapy received carbogen breathing, blood transfusions, or erythropoietin to increase their hemoglobin levels to nonanemic levels ( 13 g/dl) in order to overcome tumor hypoxia. A 1% complete response rate was observed. At 18 months, 6% had local recurrence and 14% had distant metastasis. Carbogen breathing and anemia correction resulted in improvements in local control, cause-specific survival, and overall survival (Fig. 6) [13].
5 Harrison, Shasha, White et al. 5 Cause-specific survival (%) Years p =.5 RT alone RT mito Figure 5. Cause-specific survival in patients with head and neck cancer receiving radiation plus a radiosensitizer or radiation alone [12]. Reprinted with permission. Aggressive management of anemia, when incorporated into the overall management strategy for advanced head and neck cancer, has the potential to provide significant improvements in clinical outcomes. In addition to the head and neck data just discussed [9, 13], opportunities exist in other sites. In patients with cervical cancer undergoing radiotherapy with or without chemotherapy, those who maintained an average weekly nadir hemoglobin level (ANWH) above 12 g/dl experienced a decrease in pelvic and distant recurrence (p <.1 and p <.5, respectively) compared with those whose ANWH fell below 12 g/dl. In this study, patients whose hemoglobin fell below 1 g/dl, 11 g/dl, or 12 g/dl, depending upon the study site, received blood transfusions in order to maintain ANWH above these levels [2]. Finally, in patients with advanced cervical cancer, those patients who maintained hemoglobin levels above 1 g/dl during radiotherapy had improved locoregional tumor control compared with those patients whose on-therapy values fell below 1 g/dl (p <.1) [11]. Professional awareness of the human and economic costs of anemia in patients with cancer has progressed substantially in the last decade. Most recently, research completed by The Fatigue Coalition has revealed the profound burden that fatigue imposes on patients with cancer and Actuarial local control and survival rates Percentage of patients Local control Cause-specific Overall survival survival Carbogen patients at 18 months (n = 36) Carbogen patients at 3 years (n = 36)* Noncarbogen patients at 18 months (n = 36) *Estimated probabilities Comparison group: received some chemotherapy/rt without carbogen [13] Figure 6. Actuarial local control and survival rates for patients treated with chemoradiotherapy. Data for carbogen patients at three years are estimated probabilities. Patients not receiving carbogen received the same chemoradiotherapy regimen as the carbogen group [13].
6 6 Radiotherapy-Associated Anemia their caregivers [4, 14]. In turn, recent studies have shown that modest improvements in hemoglobin concentrations can result in significant improvements in patient QOL. A recent study of epoetin alfa use in patients receiving chemotherapy demonstrated that increases in hemoglobin of less than 2 g/dl resulted in significantly improved QOL according to a questionnaire (Functional Assessment of Cancer Therapy-Anemia; FACT-An) and linear analog scale assessment (LASA) [15]. QOL improvements were observed independent of response to chemotherapy. Another study of erythropoietin use in patients undergoing chemotherapy demonstrated significant improvements in LASA scores, indicating improvement in QOL. The mean increase in hemoglobin in this study was only 1.8 g/dl [16]. Even modest anemia has a detrimental effect on clinical outcomes. Dubray [17] reported a study of head and neck cancer patients receiving radiotherapy and demonstrated that high pretreatment hemoglobin significantly related to higher survival rates. In this study, those with anemia had functional, not physiologic, anemia. All but 3 of 63 patients with anemia defined as hemoglobin <13.5 g/dl for men and hemoglobin <12. g/dl for women had hemoglobin >1 g/dl [17]. Because most of our patients also had anemia that was modest and functional, we believe the same opportunities exist to improve outcomes. CONCLUSIONS Greater awareness of the prevalence and impact of anemia in patients with cancer is an important goal for all clinicians. Although raising hemoglobin levels by 1 or 2 g/dl to 12 g/dl is easily done, historically, radiation oncologists have not given ample attention to treating moderate, or functional, anemia. The data we are collecting at Beth Israel Medical Center and St. Luke s-roosevelt Hospital Center highlight the prevalence of anemia in cancer patients. We are seeing similar data for a number of tumor sites. Increasing attention is being given to the detrimental impact anemia has on QOL, local tumor control, and overall survival. Therefore, managing anemia, even mild-tomoderate anemia, with an approach that minimizes risk to the patient and reduces undesirable side effects, is imperative if patients are to preserve QOL and improve outcomes of radiotherapy. REFERENCES 1 Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25: Grogan M, Thomas GM, Melamed I et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86: Lee WR, Berkey B, Marcial V et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG Int J Radiat Oncol Biol Phys 1998;42: Vogelzang NJ, Breitbart W, Cella D et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Int J Radiat Oncol Biol Phys 1997;34: Hollaender A, Stapleton GE, Martin FL. X-ray sensitivity of E. coli as modified by oxygen tension. Nature 1951;167: Fleming ID, Brady LW, Mieszkalski GB et al. Basis for major current therapies for cancer. In: Murphy GP, Lawrence W, Lenhard RE, eds. American Cancer Society Textbook of Clinical Oncology. Atlanta: American Cancer Society, 1995: Fyles AW, Milosevic M, Wong R et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48: Bush RS. The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 1986;12: Fein DA, Lee R, Hanlon AL et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995;13: Warde P, O Sullivan B, Bristow RG et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 1998;41: Girinski T, Pejovic-Lenfant MH, Bourhis J et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 1989;16: Haffty BG, Son YH, Papac R et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials. J Clin Oncol 1997;15: Martinez J, Cabezon M, Fuentes C et al. Hyperfractionated chemoradiotherapy with carbogen breathing for advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1999;45(suppl): Curt GA, Breitbart W, Cella DF et al. Impact of cancerrelated fatigue on the lives of patients. Proc Am Soc Clin Oncol 1999;18:573A. 15 Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is indepen-
7 Harrison, Shasha, White et al. 7 dent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16: Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15: Dubray B, Mosseri V, Brunin F et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 1996;21:
Anemia is a common occurrence in cancer patients, resulting from
1072 Once-Weekly Dosing of Epoetin- Increases Hemoglobin and Improves Quality of Life in Anemic Cancer Patients Receiving Radiation Therapy Either Concomitantly or Sequentially with Chemotherapy Daniel
More informationImpact of Anemia in Patients With Head and Neck Cancer
Impact of Anemia in Patients With Head and Neck Cancer PARVESH KUMAR Department of Radiation Oncology, UMDNJ/Robert Wood Johnson Medical School, Cancer Institute of New Jersey, St. Peter s University Hospital,
More informationThe. JOHN GLASPY, a,e LAURENT DEGOS, b,e MARIO DICATO, c,e GEORGE D. DEMETRI d,e LEARNING OBJECTIVES ABSTRACT
The Oncologist Comparable Efficacy of Epoetin Alfa for Anemic Cancer Patients Receiving Platinum- and Nonplatinum-Based Chemotherapy: A Retrospective Subanalysis of Two Large, Community-Based Trials JOHN
More informationManaging Anemia in the Cancer Patient: Old Problems, Future Solutions Michael S. Gordon. doi: /theoncologist
Managing Anemia in the Cancer Patient: Old Problems, Future Solutions Michael S. Gordon The Oncologist 2002, 7:331-341. doi: 10.1634/theoncologist.7-4-331 The online version of this article, along with
More informationOrtho Biotech, Raritan, New Jersey, USA. 3. Discuss the possible relationship between tissue hypoxia and metastatic potential.
The Oncologist rhuepo and Improved Treatment Outcomes: Potential Modes of Action KIMBERLY BLACKWELL, a PERE GASCÓN, b GEORGE SIGOUNAS, c LINDA JOLLIFFE d a Duke University Medical Center, Durham, North
More informationJustus-Liebig-University of Giessen, Giessen, Germany. 1. Relate anemia to treatment outcome in a number of solid tumors.
The Oncologist rhuepo and Treatment Outcomes: the Clinical Experience CLIFFORD A. HUDIS, a SIMON VAN BELLE, b JOSE CHANG, c KARSTEN MUENSTEDT d a Memorial Sloan-Kettering Cancer Center, New York, New York,
More informationIntroduction. Keywords: cancer, anaemia, haemoglobin, radiotherapy, Tanzania. Volume 18, Number 2, April 2016
Tanzania Journal of Health Research Volume 18, Number 2, April 2016 Doi: http://dx.doi.org/10.4314/thrb.v18i2.3 Anaemia prevalence and factors associated with haemoglobin change following radiotherapy
More informationFrequency of ABO Blood Group and Decreased Level of Hemoglobin in Lung Cancer Patients
Year: 2014; Volume: 1; Issue: 1 Article ID: CR14 02; Pages: 1-6 Advances in Cancer Research & Therapy Research Article Frequency of ABO Blood Group and Decreased Level of Hemoglobin in Lung Cancer Patients
More informationESRA KAYTAN SAĞLAM, MD Istanbul University Oncology Institute
USE OF RADIOSENSITIZERS IN ONCOLOGY ESRA KAYTAN SAĞLAM, MD Istanbul University Oncology Institute According to cell type: Radiosensitive tumors (embryojenic tumors, lymphomas) Moderate sensitives (Squamous
More informationA retrospective study: the prevalence and prognostic value of anemia in patients undergoing radiotherapy for esophageal squamous cell carcinoma
Zhang et al. World Journal of Surgical Oncology 2014, 12:244 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH A retrospective study: the prevalence and prognostic value of anemia in patients undergoing radiotherapy
More informationSymptom Management and Supportive Care
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Symptom Management and Supportive Care Early Intervention with
More informationOne of the most important advances in the area of quality of life for
Cancer-Related Fatigue: New Directions for Research Supplement to Cancer 1719 Anemia and Fatigue in Cancer Patients John Glaspy, M.D. Division of Hematology-Oncology, University of California Los Angeles
More informationRadiotherapy and Oncology
Radiotherapy and Oncology 98 (2011) 28 33 Contents lists available at ScienceDirect Radiotherapy and Oncology journal homepage: www.thegreenjournal.com Phase III randomised trial The importance of haemoglobin
More informationCombined Modality Treatment of Anal Carcinoma
Combined Modality Treatment of Anal Carcinoma F. ROELOFSEN, a H. BARTELINK b a Bethesda Krankenhaus, Essen, Germany; b The Netherlands Cancer Institute/Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, The
More informationErythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in
Erythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in thoracic tumors and MICU Dr Dipesh Maskey Senior Resident Dept of Pulmonary & CCM 14 th Oct 2011 Anemia and cancer
More informationDifferent Factors May Affect Clinical Outcome of Early Laryngeal Cancer
Med. J. Cairo Univ., Vol. 81, No. 2, December: 121-126, 2013 www.medicaljournalofcairouniversity.net Different Factors May Affect Clinical Outcome of Early Laryngeal Cancer SEHAM E. ABDELKHALEK, M.D. The
More informationRESEARCH COMMUNICATION. Prognostic Significance of Hemoglobin Levels in Patients with Primary Epithelial Ovarian Carcinoma Undergoing Platinumbased
Hemoglobin Levels with Primary Epithelial Ovarian Carcinomas on Platinum-based Chemotherapy RESEARCH COMMUNICATION Prognostic Significance of Hemoglobin Levels in Patients with Primary Epithelial Ovarian
More informationClinical relevance of hemoglobin level in cervical cancer patients administered definitive radiotherapy
Acta Oncologica, 2006; 45: 695 701 ORIGINAL ARTICLE Clinical relevance of hemoglobin level in cervical cancer patients administered definitive radiotherapy KRYSTYNA SERKIES 1, ANDRZEJ BADZIO 1 & JACEK
More informationOncologist. The. Symptom Management and Supportive Care
The Oncologist Symptom Management and Supportive Care The Effectiveness of Darbepoetin Alfa Administered Every 3 Weeks on Hematologic Outcomes and Quality of Life in Older Patients With Chemotherapy-Induced
More informationErythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
BENEFITS AND RISKS OF ESAs IN CANCER MEDICAL ONCOLOGY Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer B.L. Melosky MD ABSTRACT Anemia, already common in cancer patients,
More informationCOX-2 inhibitor and irradiation. Saitama Cancer Center Kunihiko Kobayashi MD, PhD
COX-2 inhibitor and irradiation Saitama Cancer Center Kunihiko Kobayashi MD, PhD Synthesis of prostaglandins from arachidonic acid by cyclooxygenase (COX) enzymes JNCI 95:1440, 2003 Difference between
More informationABSTRACT. Keywords: Chemotherapy induced anaemia, gastrointestinal cancers, India.
An Open Labeled Two Arm Study to Evaluate the Feasibility, Quality of Life, Safety and Efficacy of Darbepoetin as Compared to Erythropoietin Inpatients with Chemotherapy Induced Anemia in Patients with
More informationApril 12, Coverage of ESAs for Patients with Conditions Other than End-Stage Renal Disease
[ASH Comments to the Centers for Medicare and Medicaid Services on coverage for Erythropoiesis Stimulating Agents (ESAs) filed electronically on April 12, 2007] April 12, 2007 The American Society of Hematology
More informationPatient and health care provider perceptions of cancer-related fatigue and pain
Support Care Cancer (2016) 24:4357 4363 DOI 10.1007/s00520-016-3275-2 ORIGINAL ARTICLE Patient and health care provider perceptions of cancer-related fatigue and pain Loretta A. Williams 1 & Chet Bohac
More informationPrognostic Impact of Hyperglycemia in Patients with Locally Advanced Squamous Cell Carcinoma of Cervix Receiving Definite Radiotherapy
Prognostic Impact of Hyperglycemia in Patients with Locally Advanced Squamous Cell Carcinoma of Cervix Receiving Definite Radiotherapy 2016.04.08 KCCH 김문홍 DM and prediabetes in cancer Negative impact on
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationORIGINAL ARTICLE. Salvage Surgery After Failure of Nonsurgical Therapy for Carcinoma of the Larynx and Hypopharynx
ORIGINAL ARTICLE Salvage Surgery After Failure of Nonsurgical Therapy for Carcinoma of the Larynx and Hypopharynx Sandro J. Stoeckli, MD; Andreas B. Pawlik, MD; Margareta Lipp, MD; Alexander Huber, MD;
More informationFDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ES...
Page 1 of 5 Home> Drugs> Drug Safety and Availability> Postmarket Drug Safety Information for Patients and Providers Drugs FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit,
More informationPost-Operative Concurrent Chemoradiation with Mitomycin-C for Advanced Head and Neck Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 2006 Post-Operative Concurrent Chemoradiation with Mitomycin-C for
More informationTreatment of Locally Advanced Rectal Cancer: Current Concepts
Treatment of Locally Advanced Rectal Cancer: Current Concepts James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 5 MARCH 1 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationA New Dose-intense Epoetin Alfa Regimen Effective in Anemic Cancer Patients Receiving Chemotherapy: An Open-label, Non Randomized, Pilot Study
A New Dose-intense Epoetin Alfa Regimen Effective in Anemic Cancer Patients Receiving Chemotherapy: An Open-label, Non Randomized, Pilot Study DANIELE SANTINI 1, BRUNO VINCENZI 1, ANNALISA LA CESA 1, VLADIMIR
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationPrognostic value of pretreatment hemoglobin level in patients with early cervical cancer
Original Article Obstet Gynecol Sci 2014;57(1):28-36 http://dx.doi.org/10.5468/ogs.2014.57.1.28 pissn 2287-8572 eissn 2287-8580 Prognostic value of pretreatment hemoglobin level in patients with early
More informationManaging anemia with epoetin alfa in patients with rectal cancer
Managing anemia with epoetin alfa in patients with rectal cancer Vaneja Velenik 1, Irena Oblak 1, Veronika Kodre 2 1 Department for Radiotherapy, Institute of Oncology, Ljubljana, Slovenia 2 Janssen-Cilag
More informationOncologist. The. Tumor Hypoxia: Causative Factors, Compensatory Mechanisms, and Cellular Response. PETER VAUPEL, a LOUIS HARRISON b
The Oncologist Tumor Hypoxia: Causative Factors, Compensatory Mechanisms, and Cellular Response PETER VAUPEL, a LOUIS HARRISON b a Institute of Physiology and Pathophysiology, University of Mainz, Mainz,
More informationEffectiveness of Chemoradiotherapy for T1b-T2 Glottic Carcinoma
Research Article imedpub Journals http://www.imedpub.com Head and Neck Cancer Research ISSN 2572-2107 DOI: 10.21767/2572-2107.100011 Abstract Effectiveness of Chemoradiotherapy for T1b-T2 Glottic Carcinoma
More informationGhadjar et al. Radiation Oncology (2015) 10:21 DOI /s y
Ghadjar et al. Radiation Oncology (2015) 10:21 DOI 10.1186/s13014-014-0319-y RESEARCH Open Access Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary
More informationUpdate on Chemotherapy- Induced Anemia and Neutropenia Therapies
Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapyinduced
More informationCost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
FORMULARY MANAGEMENT Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia PIERRE Y. CRÉMIEUX, PhD; JOHN M. FASTENAU, RPh, MPH; GEORGE KOSICKI, PhD;
More informationAnaemia & Cancer. John de Vos Consultant Haematologist RSCH
Anaemia & Cancer John de Vos Consultant Haematologist RSCH overview Definitions & setting the scene Causes Consequences Biology Treatment Personal approach Patient Clinical team Anaemia - Definition :
More informationVol. 10, , December 1, 2004 Clinical Cancer Research 7941
Vol. 10, 7941 7949, December 1, 2004 Clinical Cancer Research 7941 Preradiotherapy Hemoglobin Level but not Microvessel Density Predicts Locoregional Control and Survival in Laryngeal Cancer Treated with
More informationImportance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy
Acta Oncologica ISSN: 0284-186X (Print) 1651-226X (Online) Journal homepage: https://www.tandfonline.com/loi/ionc20 Importance of hemoglobin concentration and its modification for the outcome of head and
More informationHALF. Who gets radiotherapy? Who gets radiotherapy? Half of all cancer patients get radiotherapy. By 1899 X rays were being used for cancer therapy
The Physical and Biological Basis of By 1899 X rays were being used for cancer therapy David J. Brenner, PhD, DSc Center for Radiological Research Department of Radiation Oncology Columbia University Medical
More informationRelationship between Changes in Hemoglobin Level and Quality of Life During Chemotherapy in Anemic Cancer Patients Receiving Epoetin Alfa Therapy
888 Relationship between Changes in Hemoglobin Level and Quality of Life During Chemotherapy in Anemic Cancer Patients Receiving Epoetin Alfa Therapy Jeffrey Crawford, M.D. 1 David Cella, Ph.D. 2 Charles
More informationInterobserver variation in cervical cancer tumor delineation for image-based radiotherapy planning among and within different specialties
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 6, NUMBER 4, FALL 2005 Interobserver variation in cervical cancer tumor delineation for image-based radiotherapy planning among and within different
More informationOncologist. The. Symptom Management and Supportive Care
The Oncologist Symptom Management and Supportive Care Prediction of the Responsiveness to Treatment with Erythropoiesis-Stimulating Factors: A Prospective Clinical Study in Patients with Solid Tumors TILMAN
More informationAnaemia in surgical patients and its effect on recovery of patients
International Surgery Journal Sonwani B et al. Int Surg J. 2016 Feb;3(1):71-76 http://www.ijsurgery.com pissn 2349-3305 eissn 2349-2902 Research Article DOI: http://dx.doi.org/10.18203/2349-2902.isj20151535
More informationRadiotherapy and Oncology 46 (1998)
Radiotherapy and Oncology 46 (1998) 135 146 A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results
More information55 th Annual Meeting American Society for Radiation Oncology. Patients: Hope Guide Heal News Briefing
55 th Annual Meeting American Society for Radiation Oncology Patients: Hope Guide Heal News Briefing Sunday, September 22, 2013 4:45 p.m. 5:15 p.m. Colleen A.F. Lawton, MD, FASTRO 2013 ASTRO President
More informationSanguineti s (2)Comment: When it was initially published in 2003 with a median follow-up of 3.8 years (4), the RTOG study led to a change in
Commento di due Soci AIRO pubblicati su due prestigiose riviste internazionali al Trial della forastiere et al. Long term results of RTOG:91-11 (a cura di Dr. Russi e Dr. Testolin )! Forastiere)et)al.)Long/Term)Results)of)RTOG)91/11:)A)Comparison)of)
More informationPET Assessment of Tumor Hypoxia
PET Assessment of Tumor Hypoxia Farrokh Dehdashti, M.D. Mallinckrodt Institute of Radiology Washington University St. Louis, Missouri 9/30/10 This work was supported by National Institute of Health R21
More informationPelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer
Pelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer Esten S. Nakken MD PhD Division of Cancer Medicine Oslo University Hospital
More informationWhat are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Ortega A, Dranitsaris G, Puodziunas A L
What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Ortega A, Dranitsaris G, Puodziunas A L Record Status This is a critical abstract of an economic evaluation
More informationJMSCR Vol 06 Issue 12 Page December 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i12.15 Single Institutional Comparative
More informationReliable data on the costs and outcomes of different
The Costs of Cancer to a Major Employer in the United States: A Case-Control Analysis Arnold Barnett, PhD; Howard Birnbaum, PhD; Pierre-Yves Cremieux, PhD; A. Mark Fendrick, MD; and Mitchell Slavin, PharmD
More informationEffective Health Care
Number 3 Effective Health Care Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Executive Summary Background Anemia (deficiency of red blood
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationRe-audit of Radiotherapy Waiting Times 2005
Abstract Re-audit of Radiotherapy Waiting Times 2005 E. Summers, M Williams Royal College of Radiologists, 38 Portland Place, London W1B 4JQ, UK Aim: To determine current waiting times for radiotherapy
More informationImpact of Long-Acting Growth Factors on Practice Dynamics and Patient Satisfaction
Impact of Long-Acting Growth Factors on Practice Dynamics and Patient Satisfaction Roy A. Beveridge, M.D., Robert M. Rifkin, M.D., Ronald J. Moleski, Pharm.D., Gary Milkovich, B.S., John F. Reitan, Pharm.D.,
More informationMiriam Kimel, PhD, Nancy K. Leidy, PhD, Sally Mannix, BA, Julia Dixon, BS
Volume 11 Number 1 2008 VALUE IN HEALTH Does Epoetin Alfa Improve Health-Related Quality of Life in Chronically Ill Patients with Anemia? Summary of Trials of Cancer, HIV/AIDS, and Chronic Kidney Disease
More informationRadiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
More informationTREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy
TREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy Anurag K. Singh, MD Professor of Medicine University at Buffalo School of Medicine Professor of Oncology Director of Radiation Research Roswell Park
More informationSource of effectiveness data The estimate for final outcomes was based on a synthesis of completed studies.
Cost effectiveness, quality-adjusted life-years and supportive care: recombinant human erythropoietin as a treatment of cancer-associated anaemia Cremieux P, Finkelstein S N, Berndt E R, Crawford J, Slavin
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationI Get Tired for No Reason: A Single Item Screening for Cancer-Related Fatigue
Vol. 22 No. 5 November 2001 Journal of Pain and Symptom Management 931 Original Article I Get Tired for No Reason: A Single Item Screening for Cancer-Related Fatigue Kenneth L. Kirsh, MS, Steven Passik,
More informationIntraoperative Radiotherapy
Intraoperative Radiotherapy Policy Number: 8.01.08 Last Review: 10/2018 Origination: 10/1988 Next Review: 10/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for radiation
More informationCountry Presentations of FNCA FY2007 Workshop on Radiation Oncology
Country Presentations of FNCA FY2007 Workshop on Radiation Oncology Annex 3 Country presentations on CERVIX-III -China: Total Patients: 18, 8 alive: 1 with metastasis lung, another one metastasis to liver;
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationClinical features and prognostic factors in patients with nasopharyngeal carcinoma relapse after primary treatment
Page 1 of 7 Clinical features and prognostic factors in patients with nasopharyngeal carcinoma relapse after primary treatment X Peng 1, SF Chen 2, C Du 2 *, P Yang 2, SX Liang 2, G Zhang 3, X Dong 4 *,
More informationCombined chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer
Journal of BUON 7: 47-51, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Combined chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer S. Isaković-Vidović,
More informationChanging Patient Perceptions of the Side Effects of Cancer Chemotherapy
155 Changing Patient Perceptions of the Side Effects of Cancer Chemotherapy Nadége Carelle, R.Ph. 1 Estelle Piotto, 1 Agnés Bellanger, Pharm.D. 1 Jerome Germanaud, 1 Alain Thuillier, M.D. 1 David Khayat,
More informationJune 12, Dear Dr. Phurrough:
June 12, 2007 Steve E. Phurrough, MD, MPA Director, Coverage and Analysis Group Centers for Medicare & Medicaid Services Mail Stop C1-09-06 7500 Security Boulevard Baltimore, MD 21244 Dear Dr. Phurrough:
More informationLaryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation
1 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing
More informationHypofractionated RT in Cervix Cancer. Anuja Jhingran, MD
Hypofractionated RT in Cervix Cancer Anuja Jhingran, MD Hypofractionated RT in Cervix Cancer: Clinicaltrials.gov 919 cervix trials 134 hypofractionated RT trials Prostate, breast, NSCLC, GBM 0 cervix trials
More informationdoi:l0.l016/j.ijrobp
Int. 1. Radiation Oncology BioI. Phys., Vol. 73, No.1, pp. 128-135,2009 Copyright 2009 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/09/$-see front matter ELSEVIER doi:l0.l016/j.ijrobp.2008.03.059
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationSTUDY ON CHANGES OF PLASMA CELL-FREE DNA OF EPSTEIN-BARR VIRUS DURING CHEMORADIOTHERAPY OF NASOPHARYNGEAL CARCINOMA PATIENTS
Journal of military pharmacomedicine n o 12019 STUDY ON CHANGES OF PLASMA CELLFREE DNA OF EPSTEINBARR VIRUS DURING CHEMORADIOTHERAPY OF NASOPHARYNGEAL CARCINOMA PATIENTS Pham Quynh Huong 1 ; Vu Nguyen
More informationEpoetin Alfa in Cancer Patients: Evidence-Based Guidelines
954 Journal of Pain and Symptom Management Vol. 22 No. 5 November 2001 Review Article Epoetin Alfa in Cancer Patients: Evidence-Based Guidelines Robert Turner, MD, Peter Anglin, MD, Ronald Burkes, MD,
More informationAccepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience ( DOI: /hed.
DEFINING RISK LEVELS IN LOCALLY ADVANCED HEAD AND NECK CANCERS: A COMPARATIVE ANALYSIS OF CONCURRENT POSTOPERATIVE RADIATION PLUS CHEMOTHERAPY TRIALS OF THE EORTC (#22931) AND RTOG (#9501) Jacques Bernier,
More informationARROCase - April 2017
ARROCase - April 2017 Radiation Indications in the setting of Neoadjuvant chemotherapy for Breast Cancer Lauren Colbert, MD, MSCR Faculty Mentor: Benjamin Smith, MD UT MD Anderson Cancer Center 37 year
More informationTrimodality Therapy for Muscle Invasive Bladder Cancer
Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,
More informationCancer-Related Fatigue: The Scale of the Problem
Cancer-Related Fatigue: The Scale of the Problem Maarten Hofman, a Julie L. Ryan, a,b Colmar D. Figueroa-Moseley, a,c Pascal Jean-Pierre, a,d Gary R. Morrow a,e a Department of Radiation Oncology, b Department
More informationNational Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: (V2)
National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: 13-14 (V2) Produced as part of the Cancer Research UK - Public Health
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationPredictive Assays in Radiation Therapy
Outline Predictive Assays in Radiation Therapy Radiation Biology Introduction Early predictive assays Recent trends in predictive assays Examples for specific tumors Summary Lecture 4-23-2014 Introduction
More informationComparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care Hospital
Human Journals Research Article July 2017 Vol.:9, Issue: 4 All rights are reserved by Pournami A S et al. Comparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care
More informationAbscopal Effect of Radiation on Toruliform Para-aortic Lymph Node Metastases of Advanced Uterine Cervical Carcinoma A Case Report
Abscopal Effect of Radiation on Toruliform Para-aortic Lymph Node Metastases of Advanced Uterine Cervical Carcinoma A Case Report MAMIKO TAKAYA 1, YUZURU NIIBE 1, SHINPEI TSUNODA 2, TOSHIKO JOBO 2, MANAMI
More informationThe Relationship Between Cancer-Related Fatigue and Patient Satisfaction with Quality of Life in Cancer
40 Journal of Pain and Symptom Management Vol. 34 No. 1 July 2007 Original Article The Relationship Between Cancer-Related Fatigue and Patient Satisfaction with Quality of Life in Cancer Digant Gupta,
More informationCancer prevalence. Chapter 7
Chapter 7 Cancer prevalence Prevalence measures the number of people diagnosed with cancer who are still alive. This chapter presents current and historical statistics on cancer prevalence in Ontario.
More informationBENEFIT APPLICATION BLUECARD/NATIONAL ACCOUNT ISSUES
Medical Policy MP 8.01.08 BCBSA Ref. Policy: 8.01.08 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Therapy Related Policies 8.01.13 Accelerated Breast Irradiation After Breast- Conserving
More informationEvaluating the Total Costs of Chemotherapy-Induced Toxicity: Results from a Pilot Study with Ovarian Cancer Patients
Evaluating the Total Costs of Chemotherapy-Induced Toxicity: Results from a Pilot Study with Ovarian Cancer Patients ELIZABETH A. CALHOUN, CHIH-HUNG CHANG, EMILY E. WELSHMAN, DAVID A. FISHMAN, JOHN R.
More informationStudy Of Letrozole Extension. Coordinating Group IBCSG IBCSG BIG 1-07
tudy Of Letrozole Extension Coordinating Group IBCSG IBCSG 35-07 BIG 1-07 A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationDepartment of Radiotherapy & Nuclear Medicine, National Cancer Institute, Cairo University, Cairo, Egypt.
Original article Res. Oncol. Vol. 12, No. 1, Jun. 2016:10-14 Dosimetric comparison of 3D conformal conventional radiotherapy versus intensity-modulated radiation therapy both in conventional and high dose
More informationOriginal Policy Date
MP 8.01.06 Intraoperative Radiation Therapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return to Medical Policy
More informationMinesh Mehta, Northwestern University. Chicago, IL
* Minesh Mehta, Northwestern University Chicago, IL Consultant: Adnexus, Bayer, Merck, Tomotherapy Stock Options: Colby, Pharmacyclics, Procertus, Stemina, Tomotherapy Board of Directors: Pharmacyclics
More informationDr. Tareq Salah Ahmed,MD,ESMO. Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate
Dr. Tareq Salah Ahmed,MD,ESMO Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate 1 st Assiut Urology department conference,marsa Alam 3 rd February 2015 Bladder cancer
More informationIsolated Para-Aortic Lymph Nodes Recurrence in Carcinoma Cervix
J Nepal Health Res Counc 2009 Oct;7(15):103-7 Original Article Isolated Para-Aortic Lymph Nodes Recurrence in Carcinoma Cervix Ghimire S 1, Hamid S, 2 Rashid A 2 1 Bhaktapur Cancer Hospital, Bhaktapur,
More information